MRSA Notes

This is hard to believe!

“Oral ZYVOX® (linezolid) was associated with significant savings to the health care system %u2013 an average of $4,630 per patient %u2013 compared to vancomycin when used in an outpatient setting for people with certain infections, according to data to be presented today at the Infectious Diseases Society of America (IDSA) annual meeting. In the study, patients taking oral ZYVOX had fewer physician office visits, emergency room visits, hospitalizations, lab tests and other health care services, as well as lower total costs, compared to patients taking vancomycin.”

Newswise | Oral ZYVOX(r) Shows Cost Savings for Treatment of Skin Infections

Share This